Alcohol Screening and Follow-up for People with Serious Mental Illness

The percentage of patients 18 years and older with a serious mental illness, who were screened for unhealthy alcohol use and received brief counseling or other follow-up care if identified as an unhealthy alcohol user.
Note: The proposed health plan measure is adapted from an existing provider-level measure for the general population (NQF #2152: Preventive Care & Screening: Unhealthy Alcohol Use: Screening & Brief Counseling). It was originally endorsed in 2014 and is currently stewarded by the American Medical Association (AMA-PCPI).

Date Reviewed: July 21, 2018
Do Not Support: Uncertain Validity
    Health Plan

Measure Info

NQF 2599 NQF Endorsed
Measure Type
Process
Measure Steward
National Committee for Quality Assurance
Clinical Topic Area
Prevention and Wellness
Substance Use
Care Setting
Outpatient
Data Source
Claims
Electronic Health Records
Paper Medical Records

ACP does not support NQF measure #2599: “Alcohol Screening and Follow-up for People with Serious Mental Illness.” Implementation will lead to meaningful improvements in clinical outcomes because comorbid alcohol use incredibly complicates the care of patients with serious mental illness; however, we note several suggestions for the developers to consider when they submit the measure to NQF for re-endorsement. First, the benefit of implementing a measure to specifically target patients who are diagnosed with serious mental illness is unclear. Sample sizes from studies of individuals with serious mental illness are small (n= <100). The United States Preventive Services Task Force (USPSTF) recommends screening in ALL patients. Second, the requirement for two counseling episodes is not based on high-quality evidence. Third, to limit confusion associated with data collection, developers should separate the numerator into two discrete measures: 1) patients who are screened for unhealthy alcohol use, 2) patients who screened positive and received counseling. Fourth, specifications should include pharmacotherapy as an alternative treatment option. Finally, while this measure is appropriately specified to assess performance at the health-plan-level of analysis, burden associated with data collection may be high for individual clinicians. While health plans can easily obtain detailed clinical management data form various information systems (e.g., claims, EHRs, pharmacy), clinicians are not privy to the same information. Additionally, the denominator population for individual clinicians may be too small to produce stable estimates.